iBio, Inc.

NASDAQ:IBIO

Biotechnology

Healthcare
$0.85 +0.00%

+$0.00 today

Market cap
$59.75M
Beta
1.29
P/E (TTM)
-3.6
EPS (TTM)
-$0.32
52W Low $0.78High $3.82

Volume 0.84M

Average 0.81M

IBIO Income Before Tax

Profit after all operating and non-operating items but before income tax.

iBio, Inc.NASDAQ: IBIO

Income Before Tax · Q4 FY2026 · quarter ended Jun 2026

Income before tax remains negative

Q4 FY2026 income before tax was -$10.6M, compared with -$5.16M a year earlier. Trailing-twelve-month income before tax was -$33.04M.

Context

  • Income before tax amounted to 33044.0% of revenue in FY2026, up 28449.8 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.
  • FY2026 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$10.6M or moves back toward the trailing-twelve-month quarterly average of -$8.26M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$10.6M-37.1% QoQ
Last fiscal yearJun 2026
-$33.04M-79.8% YoY
LTMJun 2026
-$33.04M-79.8% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-105.3%——
1 year-79.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2026
(33.04M) USD
Year-over-year change
-79.8%

Income Before Tax vs competitors

How IBIO compares with its peers on the latest reported figures

  • IBIO's LTM Jun 2026 income before tax of -$33.04M is the 2nd highest of the 4 companies compared; the peer median is -$34.55M.
  • Its year-over-year change of -79.8% is the lowest of 4, against a peer median of +23.8%.
  • Income before tax amounts to 33044.0% of revenue for IBIO, versus a peer median of 911.1%.
IBIO Competitors Peer median
Income Before Tax for IBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RLYBRallybio CorporationLTM Mar 2026-$7.82M +83.8%—911.1%
IBIOiBio, Inc.LTM Jun 2026-$33.04M -79.8%—33044.0%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026-$34.55M +23.8%——
BOLDBoundless Bio, Inc.LTM Mar 2026-$55.99M +14.8%——
Peer median (excluding IBIO) -$34.55M+23.8%—911.1%

Competitors are the stored peer set for IBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue1.88M0225K400K100K
Cost of Revenue3.79M0000
Gross Profit(1.91M)0225K400K100K
Gross Margin-101.2%—100.0%100.0%100.0%
Research & Development9.83M10.33M5.19M8.31M19.64M
Selling, General & Admin17.96M18.45M11.67M10.69M10.6M
Operating Expenses27.79M29.34M16.86M19M35.24M
Depreciation & Amortization3.79M1.38M1.25M1.13M646K
EBITDA(25.72M)(27.85M)(14.02M)(17.04M)(32.35M)
EBITDA Margin-1365.3%—-6231.6%-4259.8%-32345.0%
Operating Income(29.7M)(29.34M)(16.63M)(18.6M)(35.14M)
Operating Margin-1576.3%—-7392.9%-4650.5%-35141.0%
Interest Income177K213K363K437K2.15M
Interest Expense1.41M83K172K212K53K
Other Income / Expenses184K32K1.19M225K2.1M
Income Before Tax(29.51M)(29.31M)(15.44M)(18.38M)(33.04M)
Pre-Tax Margin-1566.5%—-6863.6%-4594.3%-33044.0%
Income Tax Expense00000
Net Income(50.39M)(65.01M)(24.91M)(18.38M)(33.04M)
Net Margin-2674.7%—-11069.8%-4594.3%-33044.0%
EPS (Basic)(2,889.06)(106.18)(6.50)(1.75)(0.32)
EPS (Diluted)(2,889.06)(106.18)(6.50)(1.75)(0.32)
Weighted Avg Shares17.44K612.25K3.83M10.5M104.06M
Weighted Avg Shares (Diluted)17.44K612.25K3.83M10.5M104.06M

iBio, Inc.

NASDAQ:IBIO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.